



Division: Pharmacy Policy	Subject: Prior Authorization Criteria
Original Development Date: Original Effective Date: Revision Date:	June 4, 2015 January 29, 2016, June 8, 2018

DALVANCE® (dalbavancin)

LENGTH OF AUTHORIZATION: UP TO TWO WEEKS

CLINICAL NOTES:

Dalbavancin is a second-generation glycopeptide antibiotic. It is approved for acute bacterial skin and skin structure infections caused by susceptible bacteria like *Staphylococcus aureus* (including methicillin-sensitive and methicillin-resistant strains) and *Streptococcus pyogenes*.

INITIAL REVIEW CRITERIA:

- Patient must be ≥ 18 years old AND
- Patient has been diagnosed with a bacterial skin/skin structure infection likely due to a gram positive organism (e.g. cellulitis or wound abscess). Dalvance is not indicated for use in other sites of infection such as urinary tract infections or pneumonia; AND
- Patient must have medical documentation of trial and failure of vancomycin for the current active infection or a culture and sensitivity report indicating the gram positive organism is resistant to vancomycin.

DOSING & ADMINISTRATION:

- Single dose regimen: 1500mg IV over 30 minutes.
- Two dose regimen: 1000 mg IV one time then 500 mg IV one week later.
- Dosage Form: 500 mg powder for injection